Key Points
- Director Christopher Patusky sold 2,910 UTHR shares on April 24 at an average price of $569 (≈$1.656M), cutting his holding by 66.14% to 1,490 shares; he also sold 1,000 shares on April 17 at $578.88.
- United Therapeutics reported $7.70 EPS for the quarter (vs. $6.78 consensus) with revenue up 7.4% YoY to $790.2M, and analysts maintain a consensus "Moderate Buy" with an average price target of $601.50.
- The stock has a market cap of $24.86 billion, trades near its 1‑year high ($607.89), and is heavily institutionally owned at about 94.08%.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 364 shares of the company's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40. Following the sale, the chief financial officer directly owned 18,996 shares in the company, valued at approximately $10,938,846.60. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
James Edgemond also recently made the following trade(s):
- On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total transaction of $5,513,815.56.
- On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00.
- On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00.
- On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
- On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total transaction of $5,778,900.00.
- On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
- On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total value of $5,931,700.00.
- On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total value of $5,359,000.00.
- On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00.
United Therapeutics Stock Performance
Shares of NASDAQ UTHR opened at $567.16 on Friday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $607.89. The stock has a market cap of $24.86 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The stock has a fifty day moving average of $536.51 and a 200-day moving average of $494.03.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. During the same quarter in the prior year, the firm posted $6.19 EPS. The firm's quarterly revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts predict that United Therapeutics Corporation will post 27.97 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. TD Cowen raised their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a report on Monday, March 30th. Finally, Royal Bank Of Canada raised their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $601.50.
Get Our Latest Stock Report on UTHR
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of UTHR. Root Financial Partners LLC raised its stake in United Therapeutics by 134.8% in the first quarter. Root Financial Partners LLC now owns 324 shares of the biotechnology company's stock valued at $192,000 after purchasing an additional 186 shares in the last quarter. IFM Investors Pty Ltd purchased a new position in United Therapeutics in the 1st quarter worth approximately $5,264,000. Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of United Therapeutics by 0.3% in the 1st quarter. Lansforsakringar Fondforvaltning AB publ now owns 13,396 shares of the biotechnology company's stock worth $7,944,000 after buying an additional 39 shares during the last quarter. Apollon Wealth Management LLC bought a new position in shares of United Therapeutics in the 1st quarter worth $7,880,000. Finally, Janney Montgomery Scott LLC raised its position in shares of United Therapeutics by 2.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 35,104 shares of the biotechnology company's stock valued at $20,816,000 after buying an additional 735 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
